Immunity to breast cancer in mice immunized with X-irradiated breast cancer cells modified to secrete IL-12

Journal of Immunotherapy

Volumn 22, Issue 5, 1999, Pages 415-422

  Carr Brendel, Victoria ^a   Markovic, Dubravka ^a   Smith, Michael ^b   Taylor Papadimitriou, Joyce ^b   Cohen, Edward P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; IL 12; Immunity; Immunotherapy; Mice

Indexed keywords

CYTOKINE; INTERLEUKIN 12;

ANIMAL CELL; ARTICLE; BREAST ADENOCARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOGENICITY; CYTOKINE RELEASE; IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL CULTURE; TUMOR GROWTH; X IRRADIATION;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; CELL TRANSFORMATION, VIRAL; DISEASE PROGRESSION; INTERLEUKIN-12; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; NEOPLASM TRANSPLANTATION; PLASMIDS; TIME FACTORS; TUMOR CELLS, CULTURED; VACCINES, INACTIVATED; X-RAYS;

EID: 0032832478     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199909000-00005     Document Type: Article

References (44)

1. Fearon ER, Pardoll DM, Itaya T, Golumbek PT, and Levitsky HI. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990;60:397-403.
2. Cavallo F, Pierro FD, Giovarelli M, et al. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993;53:5067-70.
3. Connor I, Bannerji R, Saito S, Heston W, Fair W, Gilboa, E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993;177:1127-34.
4. Chakravarty PK, Fuji H, Abu-hadid MM, Hsu S-C, Sood AK. Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression: potential therapeutic implications. Cancer Immunol Immunother 1992;35:347-54.
5. Russell SJ, Eccles SA, Flemming CL, Johnson CA, Collins MKL. Decreased tumorigenicity of a transplantable sarcoma following transfer and expression of IL-2 cDNA. Int J Cancer 1991;47:244-51.
6. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamanstein T, Blankenstein T. Mechanism of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon g. Proc Natl Acad Sci USA 1993;90:2774-8.
7. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-16.
8. Columbo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991;173:889-97.
9. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
10. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated g-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 1990;50:7820-5.
11. Nayak SK, McCallister T, Han LJ, Gangavalli R, Barber J, Dillman RO. Transduction of human renal carcinoma cells with human gamma-interferon gene via retroviral vector. Cancer Gene Ther 1996;3:143-50.
12. Pardoll DM. Paracrine cytokine adjuvants in cancer therapy. Annu Rev Immunol 1995; 13:399-415.
13. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Na-lesnik MA, Lotze MT. Cancer immunotherapy of established tumors with IL-12. J Immunol 1995;155:1393-1403.
14. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993;178:1223-30.
15. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-9.
16. Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arioli I, Parmiani G, Colombo MP. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor associated antigens. J Immunol 1996; 157:5536-42.
17. Brunda MJ, Luistro L, Henderzak JA, et al. Role of interferon-g in mediating the anti tumor efficacy of IL-12. J. Immunother 1995;17:71-7.
18. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotype stability. Invasion Met 1983;3:22-31.
19. Fulton AM, Heppner GH. Relationships of prostaglandin and natural killer sensitivity to metastatic potential in murine mammary adenocarcinomas. Cancer Res 1985;45:4779-84.
20. van der Pouw Kraan TCTM, Boeije LCM, Smeenk RJT, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin-12 production. J Exp Med 1995;181:775-9.
21. Rieser C, Bock G, Klocker H, Bartsch G, Thumher M. Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin-12 production. J Exp Med 1997;186:1603-8.
22. Tahara M, Lotze MT. Anti tumor effects of IL-12: applications for the immunotherapy and gene therapy of cancer. Gene Ther 1995;2:96-106.
23. Tapscott SJ, Miller AD, Olson JM, et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc Natl Acad Sci USA 1994;91:8185-9.
24. Boon T, Cerottini J-C, van den Eynde, et al. Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 1994;12:337-65.
25. Boon T. Toward a genetic analysis of tumor rejection antigens. Adv Cancer Res 1992;58:177-210.
26. Germann T, Rude E. Interleukin-12. Int Arch Allergy Immunol 1995:103-12.
27. Schoenhaut DS, Chua AO, Wolitzky AG, et al. Cloning and expression of murine IL-12. J Immunol 1992;148:3433-40.
28. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, Gately MK. Coexpression of two distinct genes is required to generate secreted biactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991;88:4143-9.
29. Wolf SF, Temple PA, Kobayashi M, Trinchieri G, Perussia B. Cloning of cDNA for NKSF, a heterodimeric cytokine with multiple biologic effects on T and NK cells. J Immunol 1991;146:3074-9.
30. Kennedy MK, Picha KS, Shanebeck KD, et al. IL-12 regulates the proliferation of Thl, but not Th2 or ThO clones. Eur J Immunol 1994;24:2271-7.
31. Hendrzak JA, Brunda MJ. Antitumor and antimetastatic activity of IL-12. Curr Top Microbiol Immunol 1996;213(pt. 3):65-83.
32. Kundu N, Beaty TL, Jackson MJ, Fulton AM. Antimetastatic and antitumor activities of IL-10 in a mouse model of breast cancer. J Natl Cancer Inst 1996;88:536-41.
33. Disis L, Calenoff E, McLaughlin G, et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breastcancer. Cancer Res 1994;54:16-20.
34. Peoples GE, Goedegeburre PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995;92:432-6.
35. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hotspot. Cancer Res 1992;52:6380-4.
36. Toso JF, Oei C, Oshidari F, Tartaglia J, Paoletti E, Lyerly HK, Talib S, Weinhold KJ. MAGE-1-specific precurser cytotoxic T lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res 1996;56:16-20.
37. Jerome KR, Barnd DL, Bendt X, et al. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 1991;51:2908-16.
38. Fuije T, Mori M, Ueo H, Sugimachi K, Akioshi T. Expression of MAGE and BAGE genes in Japanese breast cancers. Ann Oncol 1997;8:369-72.
39. Domenenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995;155:4766-74.
40. Jerome KR, Domenech N, Finn OJ. Tumor-specific cytotoxic T lymphocyte clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cell transfected with polymorphic epithelial mucin cDNA. J Immunol 1992;151:1644-59.
41. Thibodeau S, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science 1993;260:816-19.
42. Gonzalez-Zulueta M, Ruppert JM, Tokino K, et al. Microsatellite instability in bladder cancer. Cancer Res 1993;53:5620-3.
43. Risinger JI, Berchuck A, Kohler MF, Watson P, Lynch HT, Boyd J. Genetic instability of microsatellites in endometrial carcinoma. Cancer Res 1993;53:5100-3.
44. Peltomaki P, Lothe R, Aaltonen LA, et al. Microsatellite instability is associated with tumors that characterize the HNPCC syndrome. Cancer Res 1993;53:5853-5.